Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

Home > Science Hub > Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)
Back to the list

March 3, 2026

Pierre Gontard1, Nathalie Bernard1, Sara Diels1, Bart Tegenbos1, Dirk Goossens1, Lien Heyrman1, Magdalena Stolarek-Januszkiewicz2, Sam Abujudeh2, Jurgen Del Favero1,Barnaby Balmforth2

You might also be interested by

Posters

Advancing B-Cell Monitoring in B-Cell-Depleting Therapies for Autoimmune Disorders

June 8, 2026

More info

Uncategorized

Accelerating spectral flow cytometry assay development for clinical trials with a flexible panel design

June 8, 2026

More info

News

Leica Biosystems and CellCarta Expand Collaborative Companion Diagnostic Development Model to Accelerate Commercialization Globally

May 29, 2026

More info

News

CellCarta and Sonic Healthcare Establish Strategic Partnership to Commercialize Companion Diagnostics Through Lab Network

May 27, 2026

More info